The FDA conducted more than 3,700 facility inspections in 2025. Environmental monitoring deficiencies, including inadequate temperature and humidity control, were among the most frequently cited findings. A single temperature excursion affecting high-value biologics can cost hundreds of thousands of dollars in product loss before the regulatory remediation costs begin. In pharmaceutical manufacturing, climate control is not a facilities management function. It is a quality system component.
That distinction changes how temporary climate control is planned, deployed, and documented. A temperature deviation in a general manufacturing plant is a productivity event. In a pharmaceutical manufacturing or packaging environment, a GMP deviation triggers an investigation under 21 CFR Part 211, a batch disposition assessment, corrective and preventive action, and potentially a regulatory notification. The cost of the climate failure is not the repair bill. It is the batch loss, the investigation burden, and the compliance exposure that compound from the moment the excursion is logged.
REIC Rentals supports pharmaceutical manufacturing and packaging facilities with temporary cooling, heating, drying, and dehumidification, as well as HVAC accessories for planned maintenance windows, seasonal capacity gaps, and emergency HVAC failures. This article covers what pharmaceutical climate control actually requires, what temporary equipment must be delivered to support GMP compliance, and how to plan before a failure creates a quality event.
What GMP Climate Requirements Actually Mean for Facilities Teams
Good Manufacturing Practice (GMP) regulations establish the environmental conditions that pharmaceutical manufacturing and packaging must maintain. Those conditions are defined by product stability studies, USP standards, and the specific regulatory frameworks that govern each product and market.
FDA regulations under 21 CFR Part 211 require that drug product storage areas maintain temperature and humidity conditions appropriate to each product, with specific ranges defined by stability studies and USP standards. Controlled cold storage is generally defined as 36 to 46 degrees Fahrenheit. Freezer storage typically falls between minus 13 and plus 14 degrees Fahrenheit. Controlled room temperature for manufacturing and packaging is generally 68 to 77 degrees Fahrenheit, with short-term excursions permitted only within validated limits.
The manufacturing environment is not the only zone with defined requirements. Warehousing and storage for raw materials, in-process product, and finished goods all have temperature and humidity specifications derived from stability requirements. QC laboratories have their own environmental requirements affecting test validity. A temporary climate strategy for a pharmaceutical facility must reflect that breadth, not just address the most visible production zone.
Why Temperature and Humidity Are Quality System Variables, Not Comfort Parameters
The framing matters operationally. A facilities team managing an HVAC maintenance window in a pharmaceutical plant is not solving a comfort problem. They are managing a quality risk with defined regulatory consequences if the conditions required for GMP-compliant operation are not maintained throughout.
Humidity deviations during tablet compression affect particle binding and tablet hardness. Coating operations require controlled humidity to achieve the film thickness and uniformity specified by quality specifications. Moisture-sensitive APIs absorb or release moisture at rates that depend on ambient relative humidity, thereby affecting potency and stability. Packaging material performance, including seal integrity and barrier properties, is humidity dependent. These are not secondary concerns. They are process variables that directly affect product quality.
Our teams regularly support pharmaceutical facilities through planned maintenance windows and seasonal capacity events. One challenge we commonly help clients navigate is integrating temporary monitoring into the facility’s existing environmental monitoring system to ensure the GMP record remains continuous, rather than creating a gap during the maintenance period. That gap can be as problematic in an FDA inspection as the maintenance event itself.
Planned Maintenance: Avoiding Quality Events During HVAC Work
Planned HVAC maintenance in a pharmaceutical facility requires more lead time and more careful sequencing than in a general industrial or commercial building. The regulatory consequence of a temperature excursion during a maintenance window, even a short one, can invalidate in-process product and trigger a quality system investigation that extends well beyond the maintenance period itself.
Pre-staging temporary climate equipment before permanent systems come offline eliminates the exposure window. The temporary system must demonstrate that it achieves and holds the required conditions before the permanent system goes down. That demonstration step, which does not apply to general industrial temporary climate deployments, requires a planning lead time that the facility and REIC Rentals jointly build into the project.
The pre-staging sequence that works in pharmaceutical environments follows a defined order:
- Temporary equipment arrives and is installed while the permanent systems remain operational.
- Equipment is commissioned and run to demonstrate that it achieves the required temperature and humidity ranges.
- Monitoring is confirmed to be continuous across both permanent and temporary system records.
- The permanent system comes offline only after the temporary system performance is confirmed.
- The return to the permanent system is coordinated to maintain continuous conditioning throughout.
This sequence is the difference between a maintenance window that passes an FDA inspection and one that generates Form 483 observations.
Seasonal Capacity Gaps: When Existing Systems Fall Short
Summer ambient conditions impose a heat load that pharmaceutical manufacturing facilities were not always designed to handle at peak levels. When design conditions are exceeded during extended heat events, manufacturing areas approach their upper temperature limits, and stability storage areas run harder to compensate. Supplemental cooling equipment deployed before conditions drift toward specification limits extends the effective capacity of permanent systems and protects the margin between actual conditions and the thresholds that trigger a quality event.
The decision to deploy supplemental cooling is most effective when made proactively, based on forecast conditions, rather than reactively after monitoring records indicate drift toward specification limits. At that point, the quality event may already be in progress, and the corrective action has shifted from prevention to investigation.
REIC Rentals supports spring planning conversations with pharmaceutical facility engineers and quality teams to assess peak summer cooling requirements, confirm equipment availability before demand across the region tightens, and produce a contingency plan that is ready to activate before the first heat event of the season.
Humidity Control: A Process Variable in Its Own Right
Humidity control in pharmaceutical manufacturing is not a comfort parameter. It is a quality control input. REIC Rentals’ drying equipment provides dehumidification for manufacturing environments where humidity is a process specification, including both refrigerant-based systems for warm-season moisture control and desiccant systems for applications requiring lower dew points or colder ambient conditions.
Cooling and dehumidification in pharmaceutical environments must be planned together rather than independently. A cooling system that reduces temperature without adequately controlling latent load may bring sensible conditions within range while allowing humidity to drift outside specification. REIC Rentals specifies equipment combinations that simultaneously maintain both temperature and humidity within their required ranges and documents performance for both parameters throughout the deployment.
Facility Expansions and Construction Within Operating Pharmaceutical Plants
Pharmaceutical facility expansions and construction within operating facilities create climate control challenges that permanent building systems are not designed to address. Construction activity in or adjacent to manufacturing areas introduces dust, moisture from wet trades, and variable heat loads that the operational HVAC was sized to manage under normal production conditions.
Temporary climate control during pharmaceutical construction phases serves three simultaneous purposes: maintaining the conditions required for ongoing manufacturing in occupied areas adjacent to active construction, providing the controlled environment that new manufacturing areas require during commissioning and qualification before permanent HVAC is operational, and managing the moisture conditions in construction zones to protect building materials and permanent systems being installed. HVAC accessories, including pressure-monitoring equipment, flexible ducting, and distribution components, enable temporary systems to maintain the pressure relationships that prevent construction contaminants from migrating into manufacturing areas.
Scenario: HVAC Maintenance During an Active Packaging Campaign
Consider a pharmaceutical packaging facility in which a central air-handling unit serving a primary blister-packaging line requires replacement. The packaging campaign cannot be interrupted. The AHU must come offline for several days, but the line must continue operating within its specified temperature and humidity ranges throughout.
A facility that has engaged REIC Rentals during the planning phase has temporary climate equipment specified, commissioned, and confirmed operational before the permanent AHU goes offline. Environmental monitoring is continuous, with records demonstrating compliance with specifications during the temporary system operation period. The packaging campaign continues without interruption. The quality record shows no deviation during the maintenance window.
The alternative, a maintenance window that produces a temperature or humidity deviation in the packaging area, triggers batch disposition assessment under the quality system, a CAPA cycle, and a documentation burden that persists for months after the maintenance is complete. The cost of that alternative consistently exceeds that of properly planned temporary climate equipment by a significant multiple. That calculation makes proactive engagement with REIC Rentals before a pharmaceutical maintenance event one of the highest-return facility decisions available.
Documentation: The Component That Distinguishes Pharmaceutical Deployments
Equipment performance documentation from a temporary climate deployment in a pharmaceutical facility is not simply an operational record. It is a GMP document that may be reviewed during FDA inspections, customer audits, and internal quality reviews.
The documentation set that REIC Rentals provides alongside equipment for pharmaceutical deployments covers equipment specifications confirming the cooling and humidity capacity of each unit, startup and commissioning records showing that the system achieved the required conditions before the product entered the zone, continuous performance data during the deployment period, and maintenance and calibration records for the deployment window.
That documentation, alongside the facility’s own environmental monitoring records and quality system investigation files, constitutes the complete GMP record that protects the facility during regulatory contact and supports batch disposition decisions following any environmental event.
Contact REIC Rentals to begin planning temporary climate support for your next pharmaceutical maintenance window, seasonal capacity event, or facility expansion. Request a quote or find a location near you to connect with the team supporting pharmaceutical manufacturing facilities in your area.
1.888.356.1880 | in**@**ic.com | reic.com
Service You Trust. Equipment You Need.
